Vericel Corp Dossier - Source-backed chat

Vericel Corp

VCELNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.04

Intrinsic Value $61.51median of 6 methods · middle span $41-$293based on filings through 30 Jun 2026

Market Price $40.14Price as of 30 Sep 2026

Significantly undervaluedIntrinsic value is 53% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (+53%)

Data confidence Sign in to view data confidence

Market Cap $2.1B

Enterprise Value $1.9B

Shares Outstanding 52.9M diluted

Moat Rating None

Next Earnings Date29 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Vericel Corp is transitioning from a high-growth, cash-burning biotech into a highly profitable, self-funded commercial leader in sports medicine and severe burn care. Driven by its flagship cartilage repair product, MACI, and the rapid adoption of the arthroscopic delivery method (MACI Arthro), the company is capturing a massive, underpenetrated total addressable market. With FDA approval secured for its new state-of-the-art Burlington manufacturing facility and a massive $197 million BARDA contract supporting NexoBrid, Vericel is uniquely positioned to scale its high-margin business model while maintaining a debt-free balance sheet.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$55.00

Mean target$60.57

High · most bullish analyst$72.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$55.0010%

Operational scale-up issues at the new Burlington facility temporarily depress gross margins. MACI Arthro surgeon training plateaus, leading to slower biopsy growth. Regulatory delays push the U.K. MHRA submission into 2027, delaying international expansion plans.

Base CaseCentral scenario

$60.5760%

Matches the consensus mean

Vericel delivers on its raised FY 2026 revenue guidance of $326M-$336M, supported by steady double-digit MACI volume growth and $5M-$6M in H2 NexoBrid BARDA procurement. Gross margins stabilize around 75% as the Burlington facility scales up commercial production, and the MACI Ankle Phase 3 study initiates on schedule in Q4 2026.

Bull CaseUpside scenario

$72.0030%

MACI Arthro adoption accelerates faster than expected, driving biopsy-to-implant conversion rates above historical averages. The Burlington facility achieves rapid operational efficiencies, pushing gross margins past 76%. Early regulatory approval from the U.K. MHRA sets up a highly successful international launch in 2027, while NexoBrid procurement under the BARDA contract exceeds initial guidance.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong economic moat protected by high regulatory barriers, complex manufacturing logistics, and high surgeon switching costs.
Robust financial profile featuring a debt-free balance sheet, over $211 million in cash and investments, and positive free cash flow.
Significant expansion opportunities including the MACI Arthro rollout, MACI Ankle clinical development, and international expansion into the U.K.

Key Investment Risks

High product concentration risk, with the MACI franchise accounting for over 80% of total revenues.
Execution risk associated with scaling up commercial manufacturing at the new Burlington facility.
Dependence on third-party payer reimbursement and maintaining high prior authorization approval rates.

Thesis Invalidation Triggers

A significant drop in MACI biopsy-to-implant conversion rates or a decline in active surgeon counts.
Severe manufacturing quality or contamination issues at the Burlington facility leading to FDA intervention.
Failure to initiate the MACI Ankle Phase 3 clinical trial or negative clinical data from the MASCOT study.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.